Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B
Scribe Therapeutics has completed an oversubscribed $100-million Series B financing, with aims to further develop its suite of custom gene-editing and delivery technologies based on molecular engineering, as well as advance a pipeline of gene-edited therapeutics for neurodegeneration and other diseases with high unmet need.
Scribe’s co-founders include 2020 Nobel laureate Jennifer Doudna, PhD, a biochemist at UC Berkeley; David Savage, PhD, scientific advisor and fellow Berkeley professor; and the company’s president and CEO Benjamin L. Oakes, PhD. As an entrepreneurial fellow at the Innovative Genomics Institute, Oakes worked in the labs of Doudna and Savage, developing CRISPR-Cas9 molecules with enhanced characteristics.
“It’s part of this community where we can all come together and discuss not only the new ideas that Scribe has, but the new ideas that are going on around the world. It’s something that we try to do quite often,” Oakes told GEN Edge, because it’s not only strategically useful but also enjoyable. “That’s what we want to do with people we like.”
Focus
